Nimmons Danielle, Limdi Jimmy K
Danielle Nimmons, Jimmy K Limdi, Inflammatory Bowel Diseases Section, The Pennine Acute Hospitals NHS Trust, Manchester BL97TD, United Kingdom.
World J Gastrointest Pharmacol Ther. 2016 Feb 6;7(1):51-65. doi: 10.4292/wjgpt.v7.i1.51.
The incidence and prevalence of inflammatory bowel disease (IBD) is increasing globally. Coupled with an ageing population, the number of older patients with IBD is set to increase. The clinical features and therapeutic options in young and elderly patients are comparable but there are some significant differences. The wide differential diagnosis of IBD in elderly patients may result in a delay in diagnosis. The relative dearth of data specific to elderly IBD patients often resulting from their exclusion from pivotal clinical trials and the lack of consensus guidelines have made clinical decisions somewhat challenging. In addition, age specific concerns such as co-morbidity; loco-motor and cognitive function, poly-pharmacy and its consequences need to be taken into account. In applying modern treatment paradigms to the elderly, the clinician must consider the potential for more pronounced adverse effects in this vulnerable group and set appropriate boundaries maximising benefit and minimising harm. Meanwhile, clinicians need to make personalised decisions but as evidence based as possible in the holistic, considered and optimal management of IBD in elderly patients. In this review we will cover the clinical features and therapeutic options of IBD in the elderly; as well as addressing common questions and challenges posed by its management.
炎症性肠病(IBD)在全球范围内的发病率和患病率都在上升。随着人口老龄化,老年IBD患者的数量也将增加。年轻和老年患者的临床特征及治疗选择具有可比性,但也存在一些显著差异。老年患者IBD的鉴别诊断范围广泛,可能导致诊断延迟。由于老年IBD患者通常被排除在关键临床试验之外,以及缺乏共识性指南,导致针对这一群体的特定数据相对匮乏,这使得临床决策颇具挑战性。此外,还需要考虑一些与年龄相关的问题,如合并症、运动和认知功能、多重用药及其后果等。在将现代治疗模式应用于老年患者时,临床医生必须考虑到这一弱势群体可能出现更明显的不良反应,并设定适当的界限,以实现利益最大化和危害最小化。同时,临床医生需要做出个性化决策,但在对老年IBD患者进行全面、审慎和优化管理时应尽可能基于证据。在本综述中,我们将涵盖老年IBD的临床特征和治疗选择,以及解决其管理中常见的问题和挑战。